Obinutuzumab‐related adverse events: A systematic review and meta‐analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Obinutuzumab‐related adverse events: A systematic review and meta‐analysis

Published:2020-12-10 Issue:2 Volume:39 Page:215-221
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Amitai Irina¹²^ORCID,Gafter‐Gvili Anat²³⁴,Shargian‐Alon Liat²³^ORCID,Raanani Pia²³,Gurion Ronit²³

Affiliation:

1. Odette Cancer Center Sunnybrook Health Sciences Center Toronto Ontario Canada

2. Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel

3. Institute of Hematology Davidoff Cancer Center Rabin Medical Center Petah Tikva Israel

4. Department of Internal Medicine A Rabin Medical Center Petah Tikva Israel

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.2828

Reference26 articles.

1. Is watch and wait still acceptable for patients with low-grade follicular lymphoma?

2. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

3. Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma

4. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

5. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endosomal escape in magnetic nanostructures: Recent advances and future perspectives;Materials Today Advances;2024-06

2. Disseminated Enterovirus Infection in a Patient Affected by Follicular Lymphoma Treated with Obinutuzumab: A Case Report and a Narrative Review of the Literature;Medicina;2024-03-18

3. Acute Thrombocytopenia Complicating the Initial Administration of Obinutuzumab: Is It More Frequent Than We Think?;Oncology and Therapy;2024-01-22

4. Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial;The Lancet Oncology;2023-12

5. Shedding light on the side effects of immunotherapies used for leukemia: an updated review of the literature;Expert Review of Anticancer Therapy;2023-10-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3